Shire, Actavis Facing Federal Antitrust Class Action Lawsuit

New to ClassAction.org? Read our Newswire Disclaimer

A New York state stock corporation is behind a proposed antitrust class action claiming four defendants—Shire LLC, Shire U.S., Inc., Actavis Elizabeth LLC and Actavis LLC—engaged in an anti-competition conspiracy to fix the market for the attention-deficit/hyperactivity disorder drug Intuniv. The 38-page complaint, filed in Massachusetts district court, alleges that in 2013 Shire entered into an unlawful non-competition agreement with Actavis in which the latter “agreed to delay marketing its less-expensive generic version” of Intuniv for nearly two years. In exchange, the lawsuit continues, Shire agreed to repay its co-defendant “effectuating a payment of tens of millions of dollars” in the form of not launching an authorized generic that would directly compete with Actavis’s generic during its 180-day exclusivity period.